News
HMA: Requirements on electronic submissions for Renewals & Variations within MRP, DCP or National procedures
19.12.2010
Most NCAs are now ready to receive electronic-only applications and applicants are therefore strongly encouraged to submit in electronic format (eCTD or NeeS) to these NCAs, even if many still
...
EMA: Scientific guideline: Concept paper on revision of: Note for Guidance on the Clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use (CPMP/BPWG/283/00), draft
19.12.2010
Subcutaneous and intramuscular immunoglobulin (SCIg/IMIg) products are prepared from pooled
human plasma from not fewer than 1000 donations and contain mainly immunoglobulin G (IgG) with a
broad
...
EMA: Regulatory and procedural guideline: Annex I variation application(s) content for live attenuated influenza vaccines, draft
19.12.2010
MAHs shall submit a Type II variation application containing the adequate quality documentation in accordance with Article 18 of Commission Regulation (EC) No 1234/2008, by the Agency recommended
...
EMA: Scientific guideline: Concept paper on revision of note for guidance for the determination of withdrawal periods for milk, draft
19.12.2010
In 2000 the note for guidance for the determination of withdrawal periods for milk (EMEA/CVMP/473/98-FINAL) was adopted by the CVMP. Paragraph 2.1.10. thereof addresses dry cow products. Dry cow
...
EMA: Scientific guideline: ICH guideline Q4B annex 7 (R2) on dissolution test – general chapter
19.12.2010
This annex is the result of the Q4B process for Dissolution Test. The proposed texts were submitted by the Pharmacopoeial Discussion Group (PDG). ...
EMA: Biosimilar medicines
19.12.2010
A similar biological or \'biosimilar\' medicine is a biological medicine that is similar to another biological medicine (the ‘biological reference medicine’) that has already been authorised
...
EMA: Scientific guideline: Draft guideline on similar biological medicinal products containing monoclonal antibodies, draft
19.12.2010
This guideline lays down the non-clinical and clinical requirements for monoclonal antibody (mAb)
containing medicinal products claiming to be similar to another one already marketed. The
...
EDQM: A Council of Europe Convention to fight against counterfeit medical products
19.12.2010
Strasbourg, 09.12.2010 – The Council of Europe Committee of Ministers
adopted a convention which, for the first time, criminalises the counterfeiting
and also manufacturing and supplying of
...
European Commission: ICH guideline E2F - Note for guidance on development safety update reports
19.12.2010
The ICH guideline E2F gives sponsors guidance as to how to draw up the yearly safety report (Article 17(2) of the \'Clinical Trials Directive\' 2001/20/EC).
To give additional support, ICH has
...
MHRA: Marketing authorisations for medicines: Decentralised Procedure slot update (December 2010) – slots available in all therapeutic areas in 2011
19.12.2010
The MHRA has slots available in all therapeutic areas, including biologicals and over-the-counter (OTC) in 2011. Companies are advised to contact the MR-DC team to enquire about
...